Year: 2025

Publication of the statement from the Board of Directors regarding Constantinsborg A/S’ voluntary cash offer to the shareholders of FirstFarms A/S

Written by Customer Service on March 17, 2025. Posted in Mergers And Acquisitions.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ANY APPLICABLE LAWS OR REGULATIONS, INCLUDING IN THE UNITED STATES OF AMERICA Publication of the statement from the Board of Directors regarding Constantinsborg A/S’ voluntary cash offer to the shareholders of FirstFarms A/S With reference to company announcement no. 2/2025 and company announcement no. 10/2025 regarding Constantinsborg A/S’ (the “Offeror”) decision to submit a voluntary cash offer for all shares in FirstFarms A/S (“FirstFarms”) (excluding treasury shares held by FirstFarms and shares already held by the Offeror) at an offer price of DKK 84.00 per share with a nominal value of DKK 10 (the “Offer”) and publication of the offer document, FirstFarms hereby publishes the statement...

Bureau Veritas strengthens its leading position in the Chilean copper market through the acquisition of GeoAssay

Written by Customer Service on March 17, 2025. Posted in Mergers And Acquisitions.

PRESS RELEASE Paris – March 17, 2025 Bureau Veritas strengthens its leading position in the Chilean copper market through the acquisition of GeoAssay Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces the acquisition of GeoAssay. This transaction cements Bureau Veritas’ position as the Metals & Minerals market leader in Chile, the world’s largest copper producer. Bureau Veritas’ Metals & Minerals operations aim to support our clients throughout the entire mining cycle, from mine to port. This is achieved by accurately determining the physical, chemical and geochemical properties of materials through our extensive network of laboratories. With a global presence in major ports around the world and with global mining and refining locations, Bureau Veritas’ footprint is expanding...

Net asset value of the EfTEN United Property Fund as of 28.02.2025

Written by Customer Service on March 17, 2025. Posted in Public Companies.

The net asset value (NAV) per unit of EfTEN United Property Fund was 11,27 euros at the end of February, up 0,4% in the month. The fund earned 117 thousand euros in net profit in February and 525 thousand euros in net profit in the first two months of the year (113 thousand euros at the same time last year). In February, EfTEN United Property Fund’s profit was negatively affected by an investment in EfTEN Real Estate Fund AS shares, which closed on the stock exchange in February at 0,3% lower than at the end of the previous month. If the fund’s investment in EfTEN Real Estate Fund AS shares were recorded on the basis of its net asset value, EfTEN United Property Fund’s NAV would be 11,33 euros, up 0,5% in the month. The decline in EfTEN Real Estate Fund’s share price was primarily offset by the results of the EfTEN...

US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients

Written by Customer Service on March 17, 2025. Posted in Public Companies.

Ad hoc announcement pursuant to Art. 53 LRFDA confirms that prescribers and pharmacists are no longer expected to interact with the REMSAllschwil, Switzerland – March 17, 2025Idorsia Ltd (SIX: IDIA) today announced that – effective immediately – the US FDA has fully released TRYVIO™ (aprocitentan) from its REMS (Risk Evaluation and Mitigation Strategy) requirement. TRYVIO is Idorsia’s dual endothelin receptor antagonist (ERA) indicated for the treatment of systemic hypertension in combination with other antihypertensives to lower blood pressure in patients who are not adequately controlled on other drugs. The US FDA has determined that a REMS is no longer necessary to ensure the benefits of TRYVIO outweigh the risk of embryo-fetal toxicity and that labeling is sufficient for conveying the safety information. The FDA have therefore...

12/2025・Trifork Group: Weekly report on share buyback

Written by Customer Service on March 17, 2025. Posted in Public Companies.

Company announcement no. 12 / 2025Schindellegi, Switzerland – 17 March 2025 Trifork Group: Weekly report on share buyback On 28 Februay 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 4 March 2025 up to and including no later than 30 June 2025. The buyback program will not be active from 9 to 15 April 2025. For details, please see company announcement no. 7 of 28 February 2025. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 256,329 treasury shares, corresponding to 1.3% of the share...

Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference

Written by Customer Service on March 17, 2025. Posted in Public Companies.

New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of individuals with Types 2 or 3 spinal muscular atrophy (SMA) Late-breaking oral on Elevidys’ Embark two-year data and pooled analysis of Study 101, 102 and Endeavor, demonstrated clinically meaningful and statistically significant improvements across key measures of motor function in boys with Duchenne muscular dystrophy (DMD) Muscle pathology as measured by MRI continued to generally favour Elevidys across muscle groups in boys with Duchenne up to two yearsBasel, 17 March 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present new data at the Muscular Dystrophy Association (MDA) conference, 16-19 March, 2025, in Dallas, Texas, from its neuromuscular portfolio, including 12 oral and...

VEON appoints Johan Buse as the Incoming CEO of Banglalink

Written by Customer Service on March 17, 2025. Posted in Public Companies.

Johan BuseJohan Buse, Incoming CEO of BanglalinkDubai and Dhaka, 17 March 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Group”), today announces that Johan Buse has been appointed as the Chief Executive Officer of Banglalink, VEON’s digital operator in Bangladesh, effective 6th April 2025. Johan joins Banglalink from StarHub in Singapore where he led the Consumer Business Group focusing on strategy and business transformation. Prior to that, Johan has decades of experience in the telecom industry across Europe, Asia and the Middle East. He previously served as the Chief Commercial Officer of Ooredoo Oman and held senior positions at Deutsche Telekom Croatia, AXIS and Singtel. Johan will succeed Erik Aas who has made the decision to move on from Banglalink after nine successful years. Commenting on...

Castellum Announces Pricing of $4.5 Million Public Offering of Common Stock and Warrants

Written by Customer Service on March 17, 2025. Posted in Public Companies.

Castellum Announces Pricing of $4.5 Million Public Offering of Common Stock and WarrantsCastellum, Inc. (the “Company” and “Castellum”) (NYSE-American: CTM) announced the pricing of its previously announced public offering of 4,500,000 Units at a public offering price of $1.00 per Unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock – www.castellumus.comVIENNA, Va., March 16, 2025 (GLOBE NEWSWIRE) — Castellum, Inc. (the “Company” and “Castellum”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, today announced the pricing of its previously announced public offering of 4,500,000 Units at a public offering price of $1.00 per Unit. Each unit consists of one share of common stock and one...

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Written by Customer Service on March 16, 2025. Posted in Public Companies.

– Continued favorable safety profile for DYNE-251 – – DELIVER Registrational Expansion Cohort is fully enrolled; data from this cohort planned for late 2025 – – Potential for Biologics License Application submission for U.S. accelerated approval in early 2026 – WALTHAM, Mass., March 16, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement at the selected registrational dose of 20 mg/kg Q4W (approximate PMO dose). The DELIVER trial is evaluating DYNE-251 in individuals with Duchenne muscular...

Qifu Technology Announces Fourth Quarter and Full Year 2024 Unaudited Financial Results and Raises Semi-Annual Dividend

Written by Customer Service on March 16, 2025. Posted in Earnings Releases And Operating Results.

SHANGHAI, China, March 16, 2025 (GLOBE NEWSWIRE) — Qifu Technology, Inc. (NASDAQ: QFIN; HKEx: 3660) (“Qifu Technology” or the “Company”), a leading AI-empowered Credit-Tech platform in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2024 and raised semi-annual dividend. Fourth Quarter 2024 Business HighlightsAs of December 31, 2024, our platform has connected 162 financial institutional partners and 261.2 million consumers*1 with potential credit needs, cumulatively, an increase of 11.0% from 235.4 million a year ago. Cumulative users with approved credit lines*2 were 56.9 million as of December 31, 2024, an increase of 11.8% from 50.9 million as of December 31, 2023. Cumulative borrowers with successful drawdown, including repeat borrowers was 34.4 million as of...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals